{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:39:20Z","timestamp":1784097560516,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T00:00:00Z","timestamp":1539648000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4891-7","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T11:10:03Z","timestamp":1539688203000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study"],"prefix":"10.1186","volume":"18","author":[{"given":"Min Kyoung","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Sook","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Won","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Min","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0278-2563","authenticated-orcid":false,"given":"Hye Sun","family":"Gwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,16]]},"reference":[{"key":"4891_CR1","unstructured":"Korea Central Cancer Registry, National Cancer Center. Annual report of cancer statistics in Korea in 2014. Sejongsi: Ministry of Health and Welfare; 2016."},{"key":"4891_CR2","doi-asserted-by":"publisher","first-page":"3798","DOI":"10.1200\/JCO.2003.11.069","volume":"21","author":"FR Hirsch","year":"2003","unstructured":"Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21:3798\u2013807.","journal-title":"J Clin Oncol"},{"key":"4891_CR3","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol. 2007;25:1960\u20136.","journal-title":"J Clin Oncol"},{"key":"4891_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"FA Shepherd","year":"2005","unstructured":"Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non\u2013small-cell lung cancer. N Engl J Med. 2005;353:123\u201332.","journal-title":"N Engl J Med"},{"key":"4891_CR5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","volume":"12","author":"C Zhou","year":"2011","unstructured":"Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735\u201342.","journal-title":"Lancet Oncol"},{"key":"4891_CR6","unstructured":"Canada R. Prescribing information Tarceva (erlotinib). 2013. \n                    http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021743s018lbl.pdf\n                    \n                  . Accessed 22 Feb 2016."},{"key":"4891_CR7","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1158\/1078-0432.CCR-07-0088","volume":"13","author":"J Li","year":"2007","unstructured":"Li J, Zhao M, He P, et al. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007;13:3731\u20137.","journal-title":"Clin Cancer Res"},{"key":"4891_CR8","first-page":"509","volume":"35","author":"J Chen","year":"2012","unstructured":"Chen J, Gu R, Wan Q, et al. Gefitinib-induced hepatotoxicity in patients treated for non-small cell lung cancer. Onkologie. 2012;35:509\u201313.","journal-title":"Onkologie"},{"key":"4891_CR9","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00280-014-2390-3","volume":"73","author":"M Hamilton","year":"2014","unstructured":"Hamilton M, Wolf JL, Drolet DW, et al. The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects. Cancer Chemother Pharmacol. 2014;73:613\u201321.","journal-title":"Cancer Chemother Pharmacol"},{"key":"4891_CR10","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1124\/dmd.109.030361","volume":"38","author":"X Li","year":"2010","unstructured":"Li X, Kamenecka TM, Cameron MD. Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile. Drug Metab Dispos. 2010;38:1238\u201345.","journal-title":"Drug Metab Dispos"},{"key":"4891_CR11","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1124\/mol.110.065839","volume":"78","author":"WC Teng","year":"2010","unstructured":"Teng WC, Oh JW, New LS, et al. Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol. 2010;78:693\u2013703.","journal-title":"Mol Pharmacol"},{"key":"4891_CR12","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1021\/tx900256y","volume":"22","author":"X Li","year":"2009","unstructured":"Li X, Kamenecka TM, Cameron MD. Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities. Chem Res Toxicol. 2009;22:1736\u201342.","journal-title":"Chem Res Toxicol"},{"key":"4891_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/jcph.1010","volume":"58","author":"S Cho","year":"2018","unstructured":"Cho S, Yee J, Kim JY, et al. Effects of concomitant medication use on Gefitinib-induced hepatotoxicity. J Clin Pharmacol. 2018;58:263\u20138.","journal-title":"J Clin Pharmacol"},{"key":"4891_CR14","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s10549-012-1995-7","volume":"133","author":"YL Teo","year":"2012","unstructured":"Teo YL, Saetaew M, Chanthawong S, et al. Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence. Breast Cancer Res Treat. 2012;133:703\u201311.","journal-title":"Breast Cancer Res Treat"},{"key":"4891_CR15","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1634\/theoncologist.6-2-162","volume":"6","author":"PD King","year":"2001","unstructured":"King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist. 2001;6:162\u201376.","journal-title":"Oncologist"},{"key":"4891_CR16","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1200\/JCO.2007.15.2280","volume":"26","author":"P Wheatley-Price","year":"2008","unstructured":"Wheatley-Price P, Ding K, Seymour L, et al. Erlotinib for advanced non\u2013small-cell lung cancer in the elderly: an analysis of the national cancer institute of Canada clinical trials group study BR.21. J Clin Oncol. 2008;26:2350\u20137.","journal-title":"J Clin Oncol"},{"key":"4891_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ejmech.2017.07.062","volume":"142","author":"GL Beretta","year":"2017","unstructured":"Beretta GL, Cassinelli G, Pennati M, et al. Overcoming ABC transporter-mediated multidrug resistance: the dual role of tyrosine kinase inhibitors as multitargeting agents. Eur J Med Chem. 2017;142:271\u201389.","journal-title":"Eur J Med Chem"},{"key":"4891_CR18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2217\/14622416.9.1.105","volume":"9","author":"FJ Sharom","year":"2008","unstructured":"Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 2008;9:105\u201327.","journal-title":"Pharmacogenomics"},{"key":"4891_CR19","first-page":"133","volume":"74","author":"M Tamura","year":"2012","unstructured":"Tamura M, Kondo M, Horio M, et al. Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and erlotinib toxicity. Nagoya J Med Sci. 2012;74:133\u201340.","journal-title":"Nagoya J Med Sci"},{"key":"4891_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2217\/pgs.10.172","volume":"12","author":"C Lemos","year":"2011","unstructured":"Lemos C, Giovannetti E, Zucali PA, et al. Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of erlotinib in non-small-cell lung cancer patients. Pharmacogenomics. 2011;12:159\u201370.","journal-title":"Pharmacogenomics"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4891-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4891-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4891-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T19:10:41Z","timestamp":1571166641000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4891-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,16]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4891"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4891-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,16]]},"assertion":[{"value":"21 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Seoul National University Hospital Institutional Review Board (IRB # H-1710-087-894). The informed consent of participants was waived by the Seoul National University Hospital Institutional Review Board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"988"}}